RD Global Monitoring anti-TFPI RES

Overview

About

This competitive program aims to support preclinical research in hemophilia that investigate strategies to evaluate hemostatic potential of anti-TFPI therapies.

Project Types and Area of Interest

Eligible projects will be considered for financial/non-financial support and will prioritize independent preclinical research aimed at enhancing the medical and scientific understanding of hemostasis in the setting of TFPI inhibition in hemophilia.

Grant requests for drug/compound only are also in scope of this RFP. The results of these studies will help prepare clinicians and laboratory specialists for the integration of novel hemophilia therapies into local standard treatment protocols.

Eligibility

_We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's [website]().
_

Application Details

Pfizer Research Grant Request for Proposals
Monitoring of Anti-TFPI Therapies in
Hemophilia
Competitive Grant Program – using Pfizer internal Review Process
Overview
This competitive program aims to support preclinical research in
hemophilia that investigate strategies to evaluate hemostatic potential
of anti-TFPI therapies.
Geographic Scope/Location of Project
US, Europe, Japan, China, Brazil and Saudi Arabia
Project Types and Area of Interest
Eligible projects will be considered for financial/non-financial support
and will prioritize independent preclinical research aimed at
enhancing the medical and scientific understanding of hemostasis in
the setting of TFPI inhibition in hemophilia.
Grant requests for drug/compound only are also in scope of this RFP.
The results of these studies will help prepare clinicians and laboratory
specialists for the integration of novel hemophilia therapies into local
standard treatment protocols.
Key Milestones
• Application submission deadline: 27 December 2024
• Anticipated decision notification date: January 2025
• Anticipated project start date: February 2025
Funding Range and Project Length
Individual projects requesting up to $50,000 USD will be
considered. Pfizer anticipates awarding 2-4 projects in total.
Anticipated project length is 12 months.

I. Eligibility
Geographic Scope:
• US, Europe, Japan, China, Brazil, and Saudi Arabia
Applicant Eligibility Criteria
• The institution and Principal Investigator (PI) must be based in one of the eligible countries noted above.
• Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an
independent group of physicians not affiliated with a hospital, academic institution, or professional
society).
• If the project involves multiple departments within an institution and/or between different institutions /
organizations / associations, all institutions must have a relevant role and the requesting organization
must have a key role in the project.
• The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing
degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
• The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research
coordinator).
• The PI must be an employee or contractor of the requesting organization.
• Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We
strongly recommend that applicants confirm this with their organization or institution prior to submitting
an application. Grants awarded to organizations that are subsequently found to be unable to accept
funding directly from Pfizer Inc. may be subject to rescission.
II. Requirements
Date RFP Issued
• 8 November 2024
Clinical Area
• Hemophilia
Specific Area of Interest for this RFP:
• The intent of this Request for Proposal (RFP) is to support preclinical research focused on strategies to
assess and monitor anti-TFPI therapies in hemophilia. Requests for Pfizer anti-TFPI compound should
be clearly justified in the project.
Expected Approximate Monetary Range of Grant Applications:
• Individual projects requesting up to $50,000 USD will be considered. Pfizer anticipates awarding 2-4
projects in total.
• Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and
indirect costs.
2

Key Dates:
• RFP Release Date: 8 November 2024
• Full Proposal Due Date: 27 December 2024
• Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
• Anticipated Full Proposal Notification Date: January 2025
• Grants will be distributed following a fully executed agreement.
How to Submit:
Note: Please read this section carefully since applications submitted not following these instructions will
not be accepted and will be cancelled.
• Please go to www.cybergrants.com/pfizer/Research and sign in. First-time users should click “Create
your password”. [Note: there are individual portals for each grant application type. Please be sure to use
the URL above.]
• Click the "Start a New Research Grant Application" button.
• In the application:
• For the question “Competitive Grant?” select “Yes”
• Select the following Competitive Grant Program Name: 2024 RD Global Monitoring anti-TFPI
RES
• Requirements for submission:
Complete all required sections of the online application and upload your project proposal (see
Appendix) in the Proposal/Protocol field.
• If you encounter any technical difficulties with the website, please click the “Technical Questions” link at
the bottom of the page.
IMPORTANT: Be advised applications submitted after the due date will not be reviewed.
Questions:
• If you have questions regarding this RFP, please direct them in writing to the Grant Officer – Amanda
Stein (amanda.j.stein@pfizer.com), with the subject line “Monitoring anti-TFPI November 2024.”
• Please click here to view Frequently Asked Questions regarding the Competitive Grant Program.
Grant Agreements:
• If your grant is approved, your institution will be required to enter into a written grant agreement with
Pfizer. Please click here to view the core terms of the agreement.
• Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless
a genuine conflict exists as between applicable law and the terms of the relevant grant agreement.
Applicant is encouraged to share the core terms with counsel for approval prior to submitting an
application.
• Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment
of grant funding may only be paid to the grantee organization.
• This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.
Review and Approval Process
• Grant requests received in response to a specific RFP are reviewed by Pfizer internal review process to
make final grant decisions.
3

Mechanism by which Applicants will be Notified:
• All applicants will be notified via email by the dates noted above.
• Applicants may be asked for additional clarification during the review period.
About Pfizer Global Medical Grants
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives
(e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical
need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that
provides detail regarding a general area of interest, sets timelines for review and approval, and uses an
internal Pfizer review process to make final grant decisions. Organizations are invited to submit an
application addressing the research gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and
ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the
independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer
must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring
of the research program. An ISR grant request cannot be submitted for a study that has already commenced
and was not originally supported by Pfizer.
4

Appendix
Specific RFP Submission Requirements
Applications will be accepted via the online portal listed in the How to Submit section. Project
Proposals/Protocols should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a
12-page limit exclusive of references. When uploading your Full Proposal please ensure it addresses the
following sections:
Goals and Objectives
• Provide the main goal of the study.
• List the objectives you plan to meet with the project.
Assessment of Need for the Project
• This should reflect your study rationale. Provide a brief description of the medical/scientific question and
the rationale of how this trial or study addresses the question.
Target Audience
• Describe the primary audience(s) targeted for this project.
• Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall
population size as well as the size of your sample population.
Project Design and Methods
• Describe concisely the research design and methods for achieving the stated goals.
Innovation
• Explain what measures you have taken to assure that this project idea is original and does not duplicate
other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects
developed either by your institution or other institutions related to this project.
Evaluation and Outcomes
• Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended
submission of (a) publication(s) to peer-reviewed journals.
Anticipated Project Timeline
• Provide an anticipated timeline for your project including project start/end dates.
• An ISR grant request cannot be submitted for a study that has already commenced and was not
originally supported by Pfizer.
Additional Information
• If there is any additional information you feel Pfizer should be aware of concerning the importance of this
project, please summarize here.
5

Organization Detail
• This information is used to assess the capability of the organizational resources available to perform the
effort proposed. Identify the facilities to be used [laboratory, animal, clinical and “other”]. If appropriate,
indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project.
Budget Detail
• The budget amount requested must be in U.S. dollars (USD).
• While estimating your budget please keep the following items in mind:
• General organizational running costs such as legal fees, insurance, heating, and lighting etc. should
be included in an Institutional Overhead (if required). These costs are not specific to a grant request
and therefore, should not appear as line items in budgets. However, costs that are specific to the
study (e.g., some countries require insurance to be taken out on a per-study basis for clinical
research) would be acceptable to be included as line items.
• The inclusion of these costs cannot cause the amount requested to exceed the budget limit set
forth in the RFP.
• Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment,
purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing
is acceptable and may be included in project budget.
• It should be noted that grants awarded through GMG cannot be used to purchase Pfizer therapeutic
agents (prescription or non-prescription).
• Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and
projects. Please click here for details.
6